Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.34 |
| ▸ | JAK3 | P52333 | 10/20 | 0.34 |
| ▸ | IKBKB | O14920 | 2/20 | 0.34 |
| ▸ | CHUK | O15111 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 4/20 | 0.33 |
| ▸ | TYK2 | P29597 | 4/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12344514 | 0.90 | IKBKB (0.35) | JAK2JAK3IKBKBCHUKJAK1 | |
| SCHEMBL3551500 | 0.90 | JAK2 (0.32) | JAK2JAK3IKBKBCHUKJAK1 | |
| SCHEMBL2766361 | 0.86 | IKBKB (0.43) | JAK2JAK3IKBKBCHUKJAK1 | |
| SCHEMBL12344633 | 0.80 | ADORA2B (0.34) | JAK2JAK3IKBKBCHUKJAK1 | |
| SCHEMBL2785063 | 0.79 | IKBKB (0.40) | JAK2JAK3IKBKBCHUKJAK1 | |
| SCHEMBL3045457 | 0.79 | GRIN1 (0.33) | GRIN1GRIN2B | |
| SCHEMBL13376655 | 0.79 | JAK2 (0.32) | JAK2JAK3 | |
| SCHEMBL2766167 | 0.79 | IKBKB (0.32) | JAK2JAK3IKBKBCHUKJAK1 | |
| SCHEMBL2768229 | 0.78 | IKBKB (0.46) | JAK2JAK3IKBKBCHUKJAK1 | |
| SCHEMBL2768739 | 0.78 | IKBKB (0.31) | JAK2JAK3IKBKBCHUKJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | IL1R1, IDO1, TLR1 | JAK2 681/4885JAK3 1250/4885IKBKB 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.